Can-Fite BioPharma

Company Overview

Snapshot

Founded in September 1994 by Ilan Cohn, Can-Fite BioPharma operates with 11–50 employees. The company has raised a total of $113.45 million across 20 funding rounds from 2 investors. In July 2025, Can-Fite BioPharma went public on the NYSE.

Business overview

Can-Fite BioPharma is an Israeli biopharmaceutical company focused on the discovery and clinical development of targeted drugs for inflammatory diseases, liver diseases, metabolic diseases, and cancer. Its core technology leverages the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target, which is highly expressed in pathological cells. The company's compounds bind to A3AR to deregulate NF-kB and Wnt signal transduction pathways, producing anti-inflammatory and anticancer effects. Can-Fite operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development, serving global markets.

Strategic signal

In September 2024, Can-Fite BioPharma announced that Vetbiolix exercised its option and licensed Piclidenoson for veterinary osteoarthritis, projecting $325 million in income for Can-Fite over the next 10 years. This strategic licensing agreement validates the commercial potential of Can-Fite's drug candidates beyond human applications and signals a significant long-term revenue stream for investors.

Company Intelligence Q&A

What was a key regulatory milestone for Can-Fite's Namodenoson in October 2024?

In October 2024, the FDA granted Orphan Drug Designation to Can-Fite’s Namodenoson for pancreatic cancer, recognizing its potential in treating a rare disease.

What significant development occurred regarding Piclidenoson in September 2024?

In September 2024, Vetbiolix exercised its option and licensed Piclidenoson for veterinary osteoarthritis, which is projected to generate $325 million in income for Can-Fite over the next 10 years.

What was the outcome of the pancreatic carcinoma clinical study with Namodenoson in September 2024?

In September 2024, Can-Fite's Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson received regulatory authorization from the Israeli Ministry of Health.

What patent was secured by Can-Fite BioPharma in November 2024?

In November 2024, Can-Fite BioPharma secured an Australian patent for its obesity drug, Namodenoson.

What clinical trial milestone did Can-Fite achieve in November 2024?

In November 2024, Can-Fite achieved a milestone with the first patient dosing in its Pancreatic Cancer Phase IIa Clinical Trial.